Our findings revealed that CRC patients with increased VSIG4 expression exhibited a diminished response to immunotherapy, such as anti‐PD‐1/PD‐L1 (p = .002) and anti‐CTLA4 (p = .020) therapy (Figure 7B). Here, VSIG4 is linked to colorectal carcinoma.